Holen Sie sich die Stockscreener-App
0.84
29.23%
0.19
Handel nachbörslich:
.81
-0.03
-3.57%
Schlusskurs vom Vortag:
$0.65
Offen:
$0.706
24-Stunden-Volumen:
5.99M
Relative Volume:
3.29
Marktkapitalisierung:
$4.92M
Einnahmen:
$4.70M
Nettoeinkommen (Verlust:
$-4.99M
KGV:
-0.1308
EPS:
-6.42
Netto-Cashflow:
$-5.29M
1W Leistung:
+29.47%
1M Leistung:
+1.82%
6M Leistung:
-93.23%
1J Leistung:
-96.73%
1-Tages-Spanne:
$0.6864
$0.8976
1-Wochen-Bereich:
$0.5148
$0.8976
52-Wochen-Spanne:
$0.5148
$108.00
Salarius Pharmaceuticals Inc Stock (SLRX) Company Profile
Firmenname
Salarius Pharmaceuticals Inc
Sektor
Branche
Telefon
346-772-0346
Adresse
2450 HOLCOMBE BLVD, HOUSTON
Vergleichen Sie SLRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SLRX
Salarius Pharmaceuticals Inc
|
0.84 | 3.81M | 4.70M | -4.99M | -5.29M | -6.42 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.15 | 118.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
812.27 | 81.61B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
422.50 | 53.69B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.94 | 49.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.00 | 37.34B | 447.02M | -1.18B | -906.14M | -6.1812 |
Salarius Pharmaceuticals Inc Stock (SLRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2020-04-27 | Eingeleitet | Ladenburg Thalmann | Buy |
Salarius Pharmaceuticals Inc Aktie (SLRX) Neueste Nachrichten
Salarius Pharmaceuticals to rebrand as Decoy Therapeutics, change ticker By Investing.com - Investing.com Australia
Salarius Pharmaceuticals stock soars on name change to Decoy Therapeutics By Investing.com - Investing.com Australia
Salarius Pharmaceuticals stock soars on name change to Decoy Therapeutics - Investing.com
Salarius Pharmaceuticals, Inc. Announces Rebranding to Decoy Therapeutics Inc. with Nasdaq Trading Under DCOY Starting January 8, 2026 - Quiver Quantitative
Biotech rebrands as Decoy Therapeutics to pursue next-gen antivirals - Stock Titan
Salarius Pharmaceuticals appeals Nasdaq delisting after bid deficiency - MSN
Salarius Pharmaceuticals shareholders re-elect directors and approve proposals at annual meeting - Investing.com Nigeria
Salarius Pharmaceuticals and Decoy Therapeutics announce merger - MSN
Salarius Pharmaceuticals (NASDAQ:SLRX) Downgraded by Wall Street Zen to Sell - Defense World
Salarius Pharmaceuticals Inc. (SLRX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Salarius Shareholders Back Directors, Executive Pay and Auditor - TipRanks
Salarius Pharmaceuticals Appeals Nasdaq Delisting After Bid Deficiency - TipRanks
Salarius Pharmaceuticals faces potential Nasdaq delisting after bid price rule breach By Investing.com - Investing.com South Africa
Salarius Pharmaceuticals shareholders re-elect directors and approve proposals at annual meeting By Investing.com - Investing.com South Africa
Hanish, director at Salarius, sells shares worth $17 By Investing.com - Investing.com Nigeria
Hanish, director at Salarius, sells shares worth $17 - Investing.com
Salarius Pharmaceuticals faces potential Nasdaq delisting after bid price rule breach - Investing.com
Salarius Pharmaceuticals (NASDAQ: SLRX) appeals Nasdaq delisting over $1.00 bid rule - Stock Titan
Salarius shareholders back directors, executive pay and auditor - MSN
Salarius announces planned corporate name change to Decoy Therapeutics - MSN
Salarius Pharmaceuticals stock tumbles after announcing $7 million discounted public offering - MSN
Can Salarius Pharmaceuticals Inc. stock hit analyst price targets2025 Valuation Update & Fast Moving Market Watchlists - Улправда
Wall Street Recap: Can Salarius Pharmaceuticals Inc. (FP10) stock hit consensus price targetsWeekly Market Report & Fast Entry Momentum Alerts - Улправда
Salarius Pharmaceuticals Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting - The Manila Times
Salarius Pharmaceuticals adjourns annual meeting over quorum shortfall - MSN
Investment Review: Will Salarius Pharmaceuticals Inc. stock benefit from infrastructure spendingWeekly Trading Summary & Fast Moving Stock Watchlists - Улправда
Salarius Pharmaceuticals Adjourns Annual Meeting Over Quorum Shortfall - TipRanks
Salarius Pharmaceuticals adjourns annual meeting due to low turnout By Investing.com - Investing.com Nigeria
Can Salarius Pharmaceuticals Inc. (FP10) stock hit consensus price targets2025 EndofYear Setup & Expert Verified Stock Movement Alerts - Улправда
Salarius Pharmaceuticals adjourns annual meeting due to low turnout - Investing.com
Is Salarius Pharmaceuticals Inc. stock gaining market share2025 Retail Activity & Stock Portfolio Risk Management - DonanımHaber
What dividend safety rating applies to Salarius Pharmaceuticals Inc. (FP10) stockPortfolio Return Report & Fast Gain Stock Tips - DonanımHaber
Is Salarius Pharmaceuticals Inc. stock affected by interest rate hikesWeekly Market Summary & Detailed Earnings Play Alerts - Улправда
What makes Salarius Pharmaceuticals Inc. stock attractive to growth fundsSwing Trade & Real-Time Stock Entry Alerts - DonanımHaber
Barbara Louise Hibner Net Worth (2025) - GuruFocus
Salarius to change name to Decoy Therapeutics, adopt DCOY ticker By Investing.com - Investing.com Nigeria
Salarius Pharmaceuticals to Change Name to Decoy Therapeutics - marketscreener.com
Salarius Pharmaceuticals (SLRX) to Rebrand as Decoy Therapeutics - GuruFocus
SLRX Insider Trading - Quiver Quantitative
Salarius to change name to Decoy Therapeutics, adopt DCOY ticker - Investing.com
Salarius Pharmaceuticals announces name and ticker change to Decoy Therapeutics - marketscreener.com
Salarius Pharmaceuticals, Inc. Transforms into Decoy Therapeutics, Inc. with NASDAQ Ticker Change to DCOY Effective January 2026 - Quiver Quantitative
Decoy Therapeutics pivots to next-gen antivirals for multi-virus threats - Stock Titan
NanOlogy names David Arthur as CEO - Fort Worth Report
Salarius Pharmaceuticals Earnings Notes - Trefis
Finanzdaten der Salarius Pharmaceuticals Inc-Aktie (SLRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
28.63%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):